Stockholders' Deficit (Tables)

12 Months Ended

Jun. 30, 2016

Summary of Options

	Number of Shares			Weighted Average Exercise Price
	2016	2015	2014	2016		2015		2014
Options outstanding, beginning of year	4,525,340	5,308,617	5,726,874	$	3.48	$	3.41	$	3.30
Options granted	880,681	955,361	1,216,729	$	2.15	$	3.82	$	4.79
Options exercised	(1,097,500)	(1,202,575)	(535,730)	$	2.53	$	2.46	$	3.36
Options expired or forfeited	(292,626)	(536,063)	(1,099,256)	$	3.88	$	4.50	$	4.35
Options outstanding, end of year	4,015,895	4,525,340	5,308,617	$	3.42	$	3.48	$	3.41
Options exercisable, end of year	2,733,842	3,115,798	4,121,942	$	3.64	$	3.27	$	3.18

Options Outstanding under Plan

		Weighted		Weighted		Weighted
	Number	average		average	Number	average
Range of	outstanding	exercise		remaining	exercisable	exercise
exercise price	at June 30, 2016	price		term (yrs.)	at June 30, 2016	price
$1.59 - 3.00	734,476	$	1.98	5.93	96,188	$	2.24
3.01 - 5.00	2,986,201		3.59	3.48	2,418,583		3.55
5.01 - 7.00	295,218		5.27	4.14	219,071		5.31
	4,015,895	$	3.42	3.98	2,733,842		3.64

Schedule of Restricted Stock Unit Weighted-Average Assumptions

The fair value of each option granted during the years ended June 30, 2016, 2015 and 2014 is estimated on the date of grant using the Black‑Scholes option‑pricing model with the following weighted-average assumptions in the following table:

	Years ended June 30,
	2016	2015	2014
Expected dividend yield	0%	0%	0%
Expected option term (years)	5.03	5.07	3.85
Expected stock price volatility	58%	57%	65%
Risk-free interest rate	1.00% - 1.64%	1.37% - 1.72%	0.03% - 1.79%

Non-Vested Restricted Stock Units

		Weighted-Average
		per Share of
		Market Value
Non-Vested Restricted Stock	Number of Awards	on  Grant Date
Non-vested at July 1, 2015	706,881	$	4.30
Restricted Units Granted(a)	272,081		2.05
Restricted Units Granted – vesting based on certain market conditions(b)	1,500,000		2.28	(c)
Vested/Exercised	(412,921)		4.16
Non-vested at June 30, 2016	2,066,041	$	2.57

^(a) For the year ended June 30, 2016, 198,864 restricted stock units were awarded to the Company’s President and Chief Executive Officer, 15,341 restricted stock units were awarded to the Company’s Chief Financial Officer and 57,876 restricted stock units were awarded to the Company’s Board of Directors.

^(b) For the year ended June 30, 2016, 1,500,000 restricted stock units were awarded to the Company’s Chairman, Chief Scientific Officer and Chief Patent Officer.

Represents fair value on date of grant determined by using Monte Carlo simulation technique.

Summary of Stock-Based Compensation Expense by Consolidated Statements of Comprehensive Loss Line Items

The following table summarizes the stock-based compensation expense by the consolidated statements of comprehensive loss line items for the fiscal years ended June 30, 2016, 2015 and 2014 (in thousands):

	Fiscal Year Ended June 30,
	2016		2015		2014
Research and development	$	2,245	$	1,673	$	1,931
General and administrative		1,496		1,116		1,287
Total expense	$	3,741	$	2,789	$	3,218

Goldenberg Agreement [Member] | Restricted Stock Units

Schedule of Restricted Stock Unit Weighted-Average Assumptions

Expected dividend	0	%
Expected option term (years)	5
Expected stock price volatility	49.6	%
Risk-free interest rate	1.32	%